Halozyme Therapeutics, Inc. (HALO) 2020年年度报告「NASDAQ」.pdf

1、Annual Report 2020This performance sets us on the path for long-term value creation as a company focused on bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies.Today,Halozyme is a leader in the conversion of intravenous biolo

2、gics to subcutaneous delivery with a strategy centered around collaborating with our pharmaceutical and biotechnology partners to help them develop products that combine our patented ENHANZE technology with their proprietary compounds.Despite the challenges faced in 2020,Halozyme was able to deliver

3、 strong execution across multiple fronts that resulted in a very successful year for the company.This performance was only possible thanks to the hard work and dedication of the entire Halozyme team and our partners,who were able to navigate and respond to the unique challenges the COVID-19 global p

4、andemic brought.Delivering on Our Commitments We entered 2020 committed to transforming Halozyme into a company focused on our ENHANZE technology.As part of this transformation,we made several financial commitments with the goal of growing shareholder value:to reduce our cost structure,achieve susta

5、inable profitability,and return capital to investors.We completed the restructuring and successfully closed out non-essential activities during 2020 and achieved the expense structure we committed to.We further achieved profitability in the second quarter as guided and have maintained profitability

6、since then.We also entered 2020 committed to capital return through a$550 million three-year share repurchase program approved by the Halozyme Board of Directors in November 2019.At the outset of 2020,we targeted repurchasing up to$150 million worth of Halozyme shares during the year,bringing the to